Filing Details
- Accession Number:
- 0001209191-21-068000
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-03 19:19:21
- Reporting Period:
- 2021-12-01
- Accepted Time:
- 2021-12-03 19:19:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1845337 | Day One Biopharmaceuticals Inc. | DAWN | Pharmaceutical Preparations (2834) | 832415215 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1863676 | C. Samuel Blackman | 395 Oyster Point Blvd, Suite 217 South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-10-22 | 1,000,000 | $0.00 | 1,386,718 | No | 5 | G | Direct | |
| Common Stock | Acquisiton | 2021-10-22 | 1,000,000 | $0.00 | 1,000,000 | No | 5 | G | Indirect | By the 2021 Blackman Family LLC |
| Common Stock | Disposition | 2021-12-01 | 5,089 | $16.62 | 1,381,629 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-12-01 | 4,502 | $17.81 | 1,377,127 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-12-01 | 409 | $18.24 | 1,376,718 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | G | Direct | |
| No | 5 | G | Indirect | By the 2021 Blackman Family LLC |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- On October 22, 2021, the Reporting Person contributed 1,000,000 shares of the Issuer's Common Stock to the 2021 Blackman Family LLC (the "Trust"), of which the Reporting Person is the sole manager, and has shared voting and dispositive power with his wife as members. The Reporting Person continues to report beneficial ownership of all of the Issuer's Common Stock held by the Trust but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest therein.
- The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.19 to $17.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $18.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.22 to $18.29 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
